Wasatch BioLabs expands service portfolio with pharmacogenomics panel, telomere sequencing, and mRNA vaccine quality control workflows.
Wasatch BioLabs has added three Oxford Nanopore-developed research-use-only assays to its service portfolio: a pharmacogenomics panel, telomere sequencing, and mRNA vaccine quality control.
The Salt Lake City-based company, a subsidiary of Renew Biotechnologies, operates from a 20,000-square-foot CLIA-registered laboratory and positions itself as the largest US sequencing service provider dedicated exclusively to long-read sequencing.
“By integrating these Oxford Nanopore assays into our services, we’re giving translational teams a way to adopt these powerful workflows with confidence,” says Steve Abbott, chief operating officer at Wasatch BioLabs, in a release. “Our expertise ensures the data is delivered with the quality, clarity, and scale needed to accelerate today’s most important research.”
Three New Assay Offerings
The pharmacogenomics panel delivers full-gene coverage, including repeats, structural variants, and hybrid alleles that are often missed by short-read methods. Wasatch BioLabs offers the panel as a service with rapid turnaround and integrated bioinformatics, along with fit-for-purpose validations to align with study needs and regulatory expectations.
The telomere sequencing workflow provides molecule-level resolution of telomere length distributions and subtelomeric methylation across individual chromosome arms. Wasatch BioLabs aims to bring this assay to scale for oncology, aging, and rare disease programs where telomere dynamics may hold biological significance.
For mRNA vaccine quality control, the service uses long reads and single-molecule resolution without amplification artifacts to provide analysis of mRNA constructs from early development through lot release and stability studies. The approach preserves features such as poly(A) tails, structural heterogeneity, and overall integrity to support product quality assessment and regulatory development.
Targeting BioPharma Applications
The new assays expand Wasatch BioLabs’ ability to support biopharma and biotech teams across applications including drug response studies, telomere biology research, and mRNA vaccine development. The company runs Oxford Nanopore’s assays through its high-capacity infrastructure and bioinformatics pipelines.
Wasatch BioLabs partners with biopharma, biotech, and academic teams to deliver sequencing solutions across genomic, transcriptomic, and epigenetic applications using its long-read sequencing platform and quality systems.
ID 64616115 © Sergunt | Dreamstime.com
